OI-1 based radiopharmaceutical / Oncoinvent - LARVOL DELTA

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy. (PubMed, Mol Cancer Ther) - "This study provides the first investigation of a PTK7-targeting antibody (OI-1) as an antibody-radionuclide conjugate (212Pb-labeled) in a preclinical model of intraperitoneal ovarian cancer. These results support further investigation of OI-1 as a candidate for targeted radionuclide therapy in PTK7-expressing cancers."

Journal • Preclinical • Oncology • Ovarian Cancer • Solid Tumor • PTK7

Oncoinvent Secures NOK 250 M in an oversubscribed Pre-IPO Funding Round (Businesswire) - “Norway Oncoinvent…announced today that the company has raised NOK 250 million in an oversubscribed pre-IPO financing round…The net proceeds from the Private Placement are expected to ensure financing past end of 2023 for its lead product candidate Radspherin®, including financing of two clinical phase 2A studies (in ovarian cancer and colorectal cancer) as well as the advancement of the company’s proprietary targeted radiotherapy candidates…‘The additional funding will allow the company to initiate preclinical development of our proprietary antibodies OI-1 and OI-3 in order to develop our pipeline of targeted radiotherapeutics one year earlier than planned.”

Financing • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer